Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label multiple-dose study of SR604 in von Willebrand disease
CTR20254811Phase 2Active
- Sponsor
- Shanghai RAAS
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SR604 in von Willebrand disease (VWD), sponsored by Shanghai RAAS. Started Dec 2025; status: active.
02
Drugs
SR604
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on CTR20254811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254811.